Drug Profile
Research programme: hormone biosimilars - Harvest Moon Pharmaceuticals
Alternative Names: EPO biosimilar - Harvest Moon; hGH biosimilar - Harvest Moon; recombinant erythropoietin biosimilar - Harvest Moon; somatotropin biosimilar - Harvest MoonLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Growth hormones; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Anaemia; Growth disorders; Somatotropin deficiency
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Anaemia in USA (SC, Injection)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Growth-disorders in USA (SC, Injection)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Somatotropin-deficiency in USA (SC, Injection)